Reading LUNG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LUNG free→Reading LUNG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LUNG free→QuarterlyIQ Insights · LUNG
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On April 29, 2026, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2026. A copy of the Company’s press release dated April 29, 2026, titled “Pulmonx Reports First Quarter 2026 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Entry into a Material Definitive Agreement. Perceptive Credit Facility On March 2, 2026 (the “Closing Date”), Pulmonx Corporation (the “Company”) entered into a Credit Agreement and Guaranty (the “Credit Agreement”) and a Security Agreement (the “Security Agreement”), with Perceptive Credit Holdings V, LP (“Perceptive”), as the initial lender, administrative agent and collateral agent. The Perceptive Credit Agreement provides for a senior secured term loan facility in an aggregate principal a…
Termination of a Material Definitive Agreement. CIBC Credit Agreement In connection with the Company’s entry into the Loan Facility, on March 2, 2026, the Company repaid all outstanding indebtedness under the Amended and Restated Loan and Security Agreement, dated March 29, 2021, as amended, among the Company and the Canadian Imperial Bank of Commerce, as lender, and terminated all its obligations and commitments thereunder. No early termination fees or penalties were incurred by the Company…
Unregistered Sales of Equity Securities. The information set forth in
Results of Operations and Financial Condition. On March 4, 2026, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the fourth fiscal quarter and year ended December 31, 2025. A copy of the Company’s press release dated March 4, 2026, titled “Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is bein…
Results of Operations and Financial Condition. On November 12, 2025, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2025. A copy of the Company’s press release dated November 12, 2025, titled “Pulmonx Reports Third Quarter 2025 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “
Results of Operations and Financial Condition. On October 27, 2025, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2025. A copy of the Company’s press release dated October 27, 2025, titled “Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit her…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Principal Executive Officer On October 21, 2025, Steven S. Williamson resigned as President and Chief Executive Officer and a member of the Board of Directors of Pulmonx Corporation (the “Company”), effective as of October 27, 2025 (the “Effective Date”). Mr. Williamson entered into a agreement with the Company dated October 24, 2025…
Results of Operations and Financial Condition. On July 30, 2025, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2025. A copy of the Company’s press release dated July 30, 2025, titled “Pulmonx Reports Second Quarter 2025 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “
Results of Operations and Financial Condition. On April 30, 2025, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2025. A copy of the Company’s press release dated April 30, 2025, titled “Pulmonx Reports First Quarter 2025 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under “
Results of Operations and Financial Condition. On February 19, 2025, Pulmonx Corporation (the “Company”) issued a press release announcing its financial results for the fourth fiscal quarter and year ended December 31, 2024. A copy of the Company’s press release dated February 19, 2025, titled “Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results” is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.